COMPARISON OF CLINICAL OUTCOME BETWEEN GEFITINIB AND ERLOTINIB TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING AN EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 OR EXON 21 MUTATIONS

被引：0
|
作者：
Lim, Sung Hee [1 ]
Lee, Ji Yun [1 ]
Kim, Moonjin [1 ]
Kim, Sungmin [1 ]
Jung, Hyunae [1 ]
Chang, Won Jin [1 ]
Choi, Moon Ki [1 ]
Sun, Jong-Mu [1 ]
Hong, Jung Yong [1 ]
Lee, Su Jin [1 ]
Ahn, Jin Seok [1 ]
Park, Keunchil [1 ]
Ahn, Myung-Ju [1 ]
机构：
[1] Samsung Med Ctr, Dept Med, Div Hematol Oncol, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
gefitinib; erlotinib; Epidermal growth factor receptor mutation;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-036
引用
收藏
页码：S1204 / S1205
页数：2
相关论文
共 50 条
  • [1] Comparison of clinical outcome between gefitinib and erlotinib treatment in patients with non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 or exon 21 mutations
    Lim, Sung Hee
    Lee, Ji Yoon
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
    Riely, GJ
    Pao, W
    Pham, DK
    Li, AR
    Rizvi, N
    Venkatraman, ES
    Zakowski, MF
    Kris, MG
    Ladanyi, M
    Miller, VA
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (03) : 839 - 844
  • [3] The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients
    Sun, Jong-Mu
    Won, Young-Woong
    Kim, Seung Tae
    Kim, Jung Hoon
    Choi, Yoon-La
    Lee, Jeeyun
    Park, Yeon Hee
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (04) : 687 - 694
  • [4] The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients
    Jong-Mu Sun
    Young-Woong Won
    Seung Tae Kim
    Jung Hoon Kim
    Yoon-La Choi
    Jeeyun Lee
    Yeon Hee Park
    Jin Seok Ahn
    Keunchil Park
    Myung-Ju Ahn
    [J]. Journal of Cancer Research and Clinical Oncology, 2011, 137 : 687 - 694
  • [5] Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations
    Won, Young-Woong
    Han, Ji-Youn
    Lee, Geon Kook
    Park, Seog-Yun
    Lim, Kun Young
    Yoon, Kyong-Ah
    Yun, Tak
    Kim, Heung Tae
    Lee, Jin Soo
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2011, 64 (11) : 947 - 952
  • [6] Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21
    Lim, Sung Hee
    Lee, Ji Yun
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : 506 - 511
  • [7] Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    Jackman, David M.
    Yeap, Beow Y.
    Sequist, Lecia V.
    Lindeman, Neal
    Holmes, Alison J.
    Joshi, Victoria A.
    Bell, Daphne W.
    Huberman, Mark S.
    Halmos, Balazs
    Rabin, Michael S.
    Haber, Daniel A.
    Lynch, Thomas J.
    Meyerson, Matthew
    Johnson, Bruce E.
    Jaenne, Pasi A.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (13) : 3908 - 3914
  • [8] EFFICACY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR BRAIN METASTASIS IN NON-SMALL CELL LUNG CANCER PATIENTS HARBORING EITHER EXON 19 OR 21 MUTATIONS
    Kim, Kyu-Pyo
    Lee, Dae-Ho
    Lee, Jungshin J.
    Suh, Cheolwon
    Kim, Sang-We
    Lee, Jae Cheol
    Choi, Chang-Min
    Jang, Se Jin
    Choi, Jene
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S657 - S657
  • [9] Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutations.
    Kim, K.
    Lee, D. H.
    Lee, J.
    Suh, C.
    Kim, S.
    Lee, J. C.
    Choi, C.
    Jang, S. J.
    Choi, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib
    Heigener, David F.
    Reck, Martin
    [J]. ADVANCES IN THERAPY, 2011, 28 (02) : 126 - 133
12345